U.S. flag

An official website of the United States government

Display Settings:

Format

Send to:

Choose Destination
Nelarabine (Atriance): CADTH Reimbursement Recommendation: Indication: Nelarabine (Atriance) for addition to front-line multiagent therapy of pediatric, adolescent, and young adult patients (aged 1 year to 30 years at diagnosis) with intermediate- or high-risk T-cell acute lymphoblastic leukemia [Internet].

Nelarabine (Atriance): CADTH Reimbursement Recommendation: Indication: Nelarabine (Atriance) for addition to front-line multiagent therapy of pediatric, adolescent, and young adult patients (aged 1 year to 30 years at diagnosis) with intermediate- or high-risk T-cell acute lymphoblastic leukemia [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Oct.

Table of contents


Supplemental Content

Search details

See more...

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...